Technology Transfer      


Quarterly newsletter from the UMDNJ Office of Technology Transfer and Business Development (formerly the Office of Patents and Licensing)

 

 

 

 

 

 

 

 

 

 July 2011

The UMDNJ Office of Patents and Licensing (OPL) has changed its name! We will now be referred to as the Office of Technology Transfer and Business Development (OTTBD) to better reflect the broad mission of the office within the university.


In This Issue
Issued U.S. Patents Available for Licensing
Recent License Agreements and Amendments
Technology Spotlight: A Novel Device for Repair of Knee Meniscus Injuries
Featured Article: UMDNJ awards multiple grants for translational research
2011BIO International Convention Meeting
News Flashes
Upcoming Events
Issued U.S. Patents Available for Licensing

Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines; (Maria Laura Gennaro)  US Patent # 7,932,373 The present invention provides polypeptides encoded by open reading frames present in the genome of Mycobacterium tuberculosis but absent from the genome of BCG and diagnostic and prophylactic methodologies using these polypeptides.

   

Method for identifying agents which modulate cell growth or survival; (Stephen Vatner, Christopher Depre) US Patent #  

7,846,683 The present invention relates to a method for identifying an agent. for modulating cell growth or survival. The method involves identification of an agent which modulates the net ratio of nuclear-localized versus cytosolic-localized H11 kinase or mutant H11 kinase in a cell. A method for diagnosing a cancer associated with H11 kinase or Akt activation in a subject is also provided.

 

Compositions and methods for enzymatic detachment of bacterial and fungal biofilms; (Jeffrey Kaplan) US Patent #

7,833,523 Isolated nucleic acid sequences and amino acid sequences for soluble, beta.-N-acetylglucosaminidase or active fragments or variants thereof which promote detachment of bacterial cells from a biofilm are provided. An isolated mutant bacteria which forms biofilm colonies which tightly adhere to surface but which are unable to release cells into the medium or spread over the surface is also provided. In additions, methods are described for modulating detachment of bacterial cells from biofilm by mutating soluble, .beta.-N-acetylglucosaminidase or altering its expression or activity are also provided. Also provided are compositions, methods and devices for preventing, inhibiting and treating bacterial infections.

 

Method for modulating inflammatory responses by altering plasma lipid levels; (Carl Hauser) US Patent #  7,879,821 A method for treating an immune-related disorder in a patient comprising administering an agent to the patient for altering the patient's plasma concentration of free cholesterol, wherein said agent is a non-statin agent and is administered in an amount sufficient to modulate the immune-related disorder.    

 
 

For additional information on any of the above issued patents, please contact the Office of Technology Transfer and Business Development at OTTBD@umdnj.edu.  

Recent License Agreements and Amendments
Non-exclusive license agreement with Berry & Associates, a research tool company, for the novel probe labeling technology developed at UMDNJ.

 

Exclusive license agreement to a spin-off company, The Incubation Factory, to the personal tonometer technology developed jointly with the New Jersey Institute of Technology.

 

Exclusive license agreement to a spin-off company to joint technology developed by UMDNJ and Rutgers University.

 

Amendment to an existing exclusive license agreement with a nutraceutical company to enable the company to continue with the ongoing commercialization efforts.

 

Co-exclusive license agreement to a start-up company for a novel nucleic acid probe technology. Using the UMDNJ technology, the company will be able to introduce a novel diagnostic test useful for clinical oncology applications.

 

Non-exclusive license agreement for molecular beacon technology.

 

Option to license agreement for molecular beacon technology.

 

UMDNJ Office of  Technology Transfer and Business Development (formerly the Office of Patents and Licensing)

  

UMDNJ Office of Patents and Licensing

UMDNJ Office of Patents and Licensing Staff

From left to right: Sue Dolci, Laura Schepps, Vince Smeraglia, Norell Hadzimichalis, Susan Rae, Tania Litvin-Vechnyak, Tejal Talati (Not shown: Lilly Cohen, Mona Daniels, Nicole O'Hara)

 

  

1 World's Fair Drive; Suite 2100

Somerset, NJ 08873

P: 732-235-9350; F: 732-235-9358

Email: OTTBD@umdnj.edu

UMDNJ OTTBD website

 

 View our profile on LinkedIn Follow us on Twitter

    

 

For suggestions on future newsletter content, including upcoming events, news flashes, and articles please email OTTBD@umdnj.edu 

  


 

Technology Spotlight:

A Novel Medical Device for Surgical Repair of Knee Meniscus Injuries

 

Drs. Dunn and Gatt

(l-r) Michael G. Dunn, PhD, associate professor and director, Orthopaedic Research Laboratories, and Charles J. Gatt, MD, chair, Department of Orthopaedics, UMDNJ-Robert Wood Johnson Medical School


The menisci of the knee joint play a critical role in the load transmission and shock absorption of the knee, and aid in joint stability and lubrication. Removal of a torn meniscus is one of the most commonly performed orthopaedic operations in the United States. However, long term outcomes are generally poor, and loss of meniscal function is a significant factor in the onset of degenerative osteoarthritis. Few treatment alternatives exist for significant meniscal deficiency, and there is currently no FDA-approved device for replacement of the meniscus.

Drs. Michael G. Dunn, Ph.D., and Charles J. Gatt Jr., M.D., both from the Department of Orthopaedic Surgery, UMDNJ-Robert Wood Johnson Medical School, have developed a novel resorbable scaffold that can be used as a temporary replacement for significantly damaged meniscal tissue. Following implantation, this scaffold will serve as a load sharing device which will slowly degrade and be replaced by new and functional meniscus-like tissue. The scaffold is an amorphous matrix primarily consisting of Type I collagen reinforced by high-strength resorbable polyarylate fibers arranged in a specific, reproducible, organizational pattern similar to that of the native meniscus. Fiber properties (diameter, mechanical strength and stiffness, durability) can be modified using alternate processing conditions. Importantly, this technology offers a method of anchoring the scaffold to the tibial plateau with the anchor points being continuous with the embedded fibers which allows for stable implantation to recapitulate the structural mechanics normally experienced by the tissue.

Drs. Dunn and Gatt are the recent recipients of a Translational Research Grant administered by the UMDNJ Office of Technology Transfer and Business Development (formerly, the Office of Patents and Licensing). Funds from this project will be used to further develop this novel meniscus replacement device technology, and to perform pre-clinical efficacy studies as required by the FDA.

To learn more about this technology and related partnering opportunities, please contact the UMDNJ Office of Technology Transfer and Business Development at OTTBD@umdnj.edu.  

Featured Article:
UMDNJ awards multiple grants for trans
lational research  

The UMDNJ Office of Technology Transfer and Business Development (formerly the Office of Patents and Licensing) has recently awarded multiple grants in response to a call for applications related to translational research.  Applications were judged confidentially by a panel of experts comprised of pharmaceutical and business development executives and grants were awarded based on innovation, stage of development, commercialization potential, patent status, and budget. 

 

Awarded topics included:  A Novel Device for Surgical Repair of Knee Meniscus Injuries,  proof of concept studies for a natural bacterial protein as an anti-leukemia, proof of concept studies for a cochleate technology for the formulation and delivery of siRNA, hairpin-shaped antiprimers for the diagnosis of minimal residual disease, and targeting of an ATPase for use in osteoporosis and fracture healing.

 

For more information about these awards and additional translational funding opportunities, please contact the UMDNJ Office of Technology Transfer and Business Development OTTBD@umdnj.edu


BIO 2011 International Convention Meeting 

BIO 2011

Members from the UMDNJ Office of Technology Transfer and Business Development (formerly, the Office of Patents and Licensing) and Clinical Research Organization attended the BIO 2011 International Convention in Washington D.C. from June 27-30th.

 

BIO was founded in 1993 and represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.

 

BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. The BIO International Convention showcases the many ways the biotechnology and life science industries work together to help heal, fuel, and feed the world.

 

Keynote topics spanned areas from global issues to the state of the industry and speakers included Former Prime Minister of Great Britain and Northern Ireland, Tony Blair.

 

UMDNJ helped to represent the high quality of research and technology available at NJ-based institutions by networking with pharmaceutical and business development executives, venture capital groups, and other institutions at an exhibition booth and in one-on-one partnering meetings.

 

For additional information on the BIO 2011 International Conference, please click here. 


News Flashes

NAME CHANGE: The Office of Technology Transfer and Business Development  

The UMDNJ Office of Patents and Licensing (OPL) has changed its name! We will now be referred to as the Office of Technology Transfer and Business Development (OTTBD) to better reflect the broad mission of the office within the university. For all future communications beyond this newsletter, we will use this new name. In addition, our new email address will be OTTBD@umdnj.edu, however any mail sent to our OPL@umdnj.edu address will still be received.


UMDNJ and NJIT License Personal Tonometer Technology for Innovative Glaucoma Testing to The Incubation Factory

UMDNJ and New Jersey Institute of Technology have executed a license agreement with The Incubation Factory, St. Louis, MO, covering their personal tonometer technology on which a patent is pending. The tonometer was developed by a research team led in part by Robert Fechtner, MD, director of the glaucoma division at UMDNJ. For more information please click here.

 

Foundation Venture Capital Group Invests in Company Developing Plaque-Reducing Dental Hygiene Products

Affineti Biologics, the most recent spin-off company from UMDNJ  technologies, has received a commitment of up to $500,000 from Foundation Venture Capital Group (FVCG) to advance its research in the development of therapeutic and diagnostic products based on new discoveries in oral biology and dental medicine. For more information, please click here. 

 

PTC Therapeutics Announces Publication of Phase 2 Data for Ataluren 

PTC Therapeutics, Inc. (PTC), a spin-off company based on UMDNJ technologies, announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal. The published three-month data showed that treatment with ataluren resulted in statistically significant improvements in chloride channel activity, CF-related cough and positive trends in lung function. For more information, please

click here 

  

UMDNJ Office of Technology Transfer and Business Development Now Offers Office Hours!  

We now offer office hours to university faculty by appointment on Tuesdays (1-4pm) in Newark and Fridays (9am-12pm) in Somerset. Stop by to discuss your research, commercial applications, invention disclosures, and much more! Please email OTTBD@umdnj.edu for more information or to schedule an appointment.  

 

Upcoming events

What University Researchers Should Know About Intellectual Property

  • September 2011 (Details TBA); Peter Butch and Gerard Norton, P.h.D., both partners in the Intellectual Property Division of the Fox Rothschild Law Firm will discuss issues related to intellectual property and patenting as they relate specifically to university researchers.
One-Day University

 

Mark your calendars for the first One-Day University on Saturday, October 22, 2011, at the Clinical Academic Building on the New Brunswick campus (additional details TBA).

 

The event will provide a day of educational sessions for New Jersey residents who want to know more about a variety of health-related topics and will feature UMDNJ faculty from many of our schools.

 

Our own Vince Smeraglia, Director of the Office of Technology Transfer and Business Development, is participating with Jim Golubieski, president of Foundation Venture Capital Group; Scott Kachlany, NJDS, founder of Actinobac Biomed and Robert Nagele, SOM, founder of Durin Technologies, who will all discuss "Amazing Science:  What's New, What's Hot, What's Happening."